A Double-Blind, Randomized, Placebo-Controlled, Sequential Group Pilot Study to Assess Safety, Tolerability, and Effectiveness of TC-5214 as Augmentation Therapy in Patients With Refractory Hypertension.
Phase of Trial: Phase I/II
Latest Information Update: 12 Sep 2013
At a glance
- Drugs Dexmecamylamine (Primary)
- Indications Hypertension
- Focus Therapeutic Use
- Sponsors Targacept
- 08 Aug 2009 Actual number of patients (1) added as reported by ClinicalTrials.gov.
- 08 Aug 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 24 Jul 2009 Planned end date changed from 1 Sep 2009 to 1 Dec 2009 as reported by ClinicalTrials.gov.